Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.

摘要: The M184V substitution in HIV-1 RT develops rapidly following initiation of therapy with 3TC and confers high-level phenotypic resistance to this drug both vitro vivo. Interestingly, the presence is also associated alteration several mechanisms relating function that include decreased RTprocessivity, reduced nucleotide-dependent primer unblocking, increased fidelity, hypersensitization other NRTIs, impaired viral fitness, delayed appearance mutations are responsible for thymidine analogues (i.e. thymidine-associated or TAMs). In addition, may affect transmission immunological response. Collectively, these factors might explain residual antiviral effect clinical benefit observed continued use combination regimens emergence M184V.